Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000723480 | SCV000225391 | pathogenic | not provided | 2014-12-08 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000174145 | SCV000611279 | pathogenic | 3-methylcrotonyl-CoA carboxylase 1 deficiency | 2017-05-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000174145 | SCV000775370 | pathogenic | 3-methylcrotonyl-CoA carboxylase 1 deficiency | 2025-01-22 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln372*) in the MCCC1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MCCC1 are known to be pathogenic (PMID: 11181649, 15359379, 22642865). This variant is present in population databases (rs544349961, gnomAD 0.03%). This premature translational stop signal has been observed in individual(s) with 3-methylcrotonyl-CoA carboxylase (MCC) deficiency (PMID: 22642865). ClinVar contains an entry for this variant (Variation ID: 193913). For these reasons, this variant has been classified as Pathogenic. |
DASA | RCV000174145 | SCV002499402 | pathogenic | 3-methylcrotonyl-CoA carboxylase 1 deficiency | 2022-04-10 | criteria provided, single submitter | clinical testing | The c.1114C>T;p.(Gln372*) variant creates a premature translational stop signal in the MCCC1 gene. It is expected to result in an absent or disrupted protein product -PVS1. This sequence change has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 193913; PMID: 22642865) -PS4. The variant is present at low allele frequencies population databases (rs544349961 – gnomAD 0.0003944%; ABraOM no frequency - https://abraom.ib.usp.br/) - PM2_supporting. The p.(Gln372*) was detected in trans with a pathogenic variant (PMID: 22642865) - PM3. In summary, the currently available evidence indicates that the variant is pathogenic. |
Baylor Genetics | RCV000174145 | SCV004194277 | pathogenic | 3-methylcrotonyl-CoA carboxylase 1 deficiency | 2024-02-23 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001275510 | SCV004241499 | pathogenic | Methylcrotonyl-CoA carboxylase deficiency | 2023-12-14 | criteria provided, single submitter | clinical testing | Variant summary: MCCC1 c.1114C>T (p.Gln372X) results in a premature termination codon, predicted to cause absence of the protein due to nonsense mediated decay, which is a commonly known mechanism for disease. The variant allele was found at a frequency of 2.4e-05 in 251408 control chromosomes (gnomAD). c.1114C>T has been reported in the literature in an individuals affected with Methylcrotonyl-CoA Carboxylase Deficiency who was compound heterozygous with another truncating variant (Grunert_2012). The following publication has been ascertained in the context of this evaluation (PMID: 22642865). Four submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Natera, |
RCV001275510 | SCV001460695 | pathogenic | Methylcrotonyl-CoA carboxylase deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |